organization · Reporting owner

Longitude Prime Fund, L.P.

Disclosed activity across 3 companies

Tapewire entity: 67423
SEC CIK: 0001865844

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Vera Therapeutics, Inc.VERA · Entity 4358	10% owner	February 06, 2023	February 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Vera Therapeutics, Inc.

Report date February 06, 2023 · Filed February 08, 2023

Jointly reported with Longitude Capital Partners IV, LLC, Longitude Prime Partners, LLC, Longitude Venture Partners IV, L.P., Tammenoms Bakker Juliet

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	1,714,285	Reported balance After 2023-02-06 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2023-02-06 · Purchase · Acquired 1,714,285 · Balance 1,714,285 F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	3,429,927	Reported balance Holding disclosure · report date 2023-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,429,927 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

RAPID MICRO BIOSYSTEMS, INC.

Report date February 04, 2026 · Filed February 06, 2026

Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, ENRIGHT PATRICK G, Tammenoms Bakker Juliet

Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectHeld by Longitude Prime Fund, L.P.	0	Reported balance After 2026-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-02-04 · Sale · Disposed 49,000 · Balance 0 F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
Class A Common StockSEC Table I · non-derivative	IndirectHeld by Longitude Venture Partners II, L.P.	4,029,245	Reported balance Holding disclosure · report date 2026-02-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,029,245 F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

Sierra Oncology, Inc.

Report date April 27, 2022 · Filed April 29, 2022

Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet, ENRIGHT PATRICK G, Longitude Prime Partners, LLC

Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2022-04-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-04-27 · Other · Disposed 175,000 · Balance 0 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2022-04-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2022-04-27 · Other · Disposed 1,964,771 · Balance 0 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,023	Reported balance After 2022-04-27 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2022-04-27 · Other · Acquired 5,023 · Balance 5,023 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6: These shares are held directly by Juliet Tammenoms Bakker.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,152	Reported balance After 2022-04-27 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2022-04-27 · Other · Acquired 2,152 · Balance 2,152 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	7,175	Reported balance After 2022-04-27 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2022-04-27 · Other · Acquired 7,175 · Balance 7,175 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8: These shares are held directly by Patrick G. Enright.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,611	Reported balance After 2022-04-27 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2022-04-27 · Other · Acquired 588 · Balance 5,611 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6: These shares are held directly by Juliet Tammenoms Bakker.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,404	Reported balance After 2022-04-27 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2022-04-27 · Other · Acquired 252 · Balance 2,404 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	8,015	Reported balance After 2022-04-27 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2022-04-27 · Other · Acquired 840 · Balance 8,015 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8: These shares are held directly by Patrick G. Enright.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.

F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.

F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.

F6: These shares are held directly by Juliet Tammenoms Bakker.

F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

F8: These shares are held directly by Patrick G. Enright.

F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 04, 2026 Filed Feb 6, 2026 16:26 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	SaleClass A Common Stock	49,000	$3.88	$190,090.60	Disclosure SEC source: 0001193125-26-041248 · ownership.xml · nonDerivative · entry 1 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 0 F1 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
February 06, 2023 Filed Feb 8, 2023 19:40 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	PurchaseClass A Common Stock	1,714,285	$7.00	$11,999,995.00	Disclosure SEC source: 0000899243-23-004349 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners IV, LLC · CIK 0001829169 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Longitude Venture Partners IV, L.P. · CIK 0001787456 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,714,285 F1 · ownership.nature: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	840	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 8 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,015 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	252	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 7 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,404 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	588	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 6 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,611 F9 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	7,175	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 5 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,175 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8 · ownership.nature: These shares are held directly by Patrick G. Enright. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	2,152	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 4 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,152 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7 · ownership.nature: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	5,023	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 3 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,023 F5 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6 · ownership.nature: These shares are held directly by Juliet Tammenoms Bakker. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	1,964,771	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4 · ownership.nature: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
April 27, 2022 Filed Apr 29, 2022 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	OtherCommon Stock	175,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016052 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2 · ownership.nature: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
February 02, 2022 Filed Feb 2, 2022 21:25 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	175,000	$27.00	$4,725,000.00	Disclosure SEC source: 0000899243-22-004271 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners III, LLC · CIK 0001713663 · 10% owner Longitude Venture Partners III, L.P. · CIK 0001674099 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 175,000 F1 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LPF and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP. Each of Mr. Enright, Ms. Tammenoms Bakker and Dr. Richardson disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionCommon Stock Warrant · Derivative	129,032	$0.00 Strike: $0.05	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 9 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 129,032 Underlying: Class A Common Stock · 129,032 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries B1 Warrant · Derivative	645,160	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 8 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series B1 Preferred Stock · 645,160 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionCommon Stock Warrant · Derivative	500,000	$0.00 Strike: $0.05	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 7 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries A1 Warrant · Derivative	2,500,000	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 6 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series A1 Preferred Stock · 2,500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries C1 Preferred Stock · Derivative	2,291,665	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 5 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 458,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries B1 Preferred Stock · Derivative	5,654,529	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 4 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,130,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionSeries A1 Preferred Stock · Derivative	8,774,007	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · derivative · entry 3 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,754,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	PurchaseClass A Common Stock	150,000	$20.00	$3,000,000.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · nonDerivative · entry 2 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 150,000 F2 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting, investment and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2021 Filed Jul 20, 2021 21:39 UTC	RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966	ConversionClass A Common Stock	3,344,038	$0.00	$0.00	Disclosure SEC source: 0000899243-21-029105 · doc4.xml · nonDerivative · entry 1 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 3,407,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC, ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the shares held by LVP II. Each of LCP II, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.